
Molecular Diagnostics: The Benefits, Costs, and Reliability of Rapid Infection Detection	
Andrea Caballero, MD Infectious Diseases May 4, 2019	
	1
No disclosures	
Just because you can does not necessarily mean you	
should	



\sim	4.1			
/ \ı	111	п	n	_
Οι	111	ш	11	t

- Rapid Diagnostics
 - History
 - Molecular testing
 - Multiplex PCR
- . Stool pathogen panel
 - 。 C diff testing
- . CSF pathogen panel
- · Respiratory pathogen panel

1917 Pneumococcal polysaccharide by immunoassay in serum and plasma

1953 Structure of DNA


1960 Radioimmunoassay (RIA)


1971 Enzyme-linked immunoassay (ELISA)


→ Lateral flow Immunoassay


1985 Polymerase chain reaction (PCR)


1988 Multiplex PCR











Hospital	Stool	CSF	Respiratory	Blood
Providence		~	~	TBD
Regional			•	
Central Peninsula	~		•	~
South Peninsula	~	V	V	•

"In seeking 'laboratory improvement' there is a great danger of establishing exhaustive microbiology as an end in itself"

- Raymond C. Bartlett

42 year old male with no past medical history presents to your clinic with one day of diarrhea, nausea and vomiting. He was at a work event two nights ago where he enjoyed deli meats, different varieties of cheese and raw oysters...

Bacteria	Viruses & Parasites	
Campylobacter spp	Adenovirus	
C. difficile	Astrovirus	
Plesiomonas shigelloides	Norovirus	
Salmonella spp	Rotavirus	
Vibrio spp	Sapovirus	
V. cholerae		
Yersinia enterocolitica	Cryptosporidium spp	
EAEC, EPEC, ETEC,	C. cayetanensis	
STEC	E. histolytica	
E. coli 0157	G. lamblia	
Shigella spp/EIEC		

	1556	samples,	from	Mav	- Sep
•	1000	ourriproo,	11 0111	IVICIY	OOP


- 。62% peds, 38% age ≥18
- _o 87% outpt, 11% inpt, 3% ED
- . Positivity rate 54%
 - 832 single organism detections
 - _o 724 multiple organisms
- . EPEC, C. difficile, EAEC

	No. of det	rctions"	Sensitivity/PPA ^b	Sensitivity/PPA ^b			Specificity/NPA ^b		
Analyte	C	FA	TP/(TP+FN)	96	95% CI (%)	TN/(TN+FP)	.%:	95% CI (%)	
Campylobacter spp.	35	58	34/35	97.1	85.1-99.9	1,497/1,521	98.4	97.7-99.0	
C. difficile	165	204	163/165	98.8	95.7-99.9	1,350/1,391	97.1	96.0-97.9	
P. shigelloides	3	18	3/3	100	29.2-100	1,538/1,553	99.0	98.4-99.5	
Salmonella spp.	31	37	31/31	100	88.8-100	1,519/1,525	99.6	99.1-99.9	
Vibrio spp.	0	2	0/0	1 1		1,554/1,556	99.9	99.5-100	
V. cholerae	0	1	0/0			1,555/1,556	99.9	99.6-100	
Y. enterocolitica	1	1	1/1	100	NA'	1,555/1,555	100	99.8-100	
EAEC	83	109	82/83	98.8	93.5-100	1,446/1,473	98.2	97.3-98.8	
EPEC	317	348	314/317	99.1	97.3-99.8	1,167/1,201	97.2	96.1-98.0	
ETEC	22	31	22/22	100	84.6-100	1,525/1,534	99.4	98.9-99.7	
STEC	33	38	33/33	100	89.4-100	1,518/1,523	99.7	99.2-99.9	
E. coli O157	3	4	3/3	100	29.2-100	34/35	97.1	85.1-99.9	
Shigella spp./EIEC (culture)d	49 (31)	49	47/49	95.9	86.0-99.5	1,505/1,507	99.9	99.5-100	
Cryptosporidium spp.	18	24	18/18	100	81.5-100	1,532/1,538	99.6	99.2-99.9	
C. cayetanensis	19	19	19/19	100	82.4-100	1,537/1,537	100	99.8-100	
E. histolytica	0	0	0/0			1,556/1,556	100	99.8-100	
G. lamblia	20	27	20/20	100	83.2-100	1,529/1,536	99.5	99.1-99.8	
Adenovirus F 40/41	44	55	42/44	95.5	84.5-99.4	1,499/1,512	99.1	98.5-99.5	
Astrovirus	7	8	7/7	100	59.0-100	1,548/1,549	99.9	99.6-100	
Norovirus GI/GII	55	70	52/55	94.5	84.9-98.9	1,483/1,501	98.8	98.1-99.3	
Rotavirus A	6	18	6/6	100	54.1-100	1,538/1,550	99.2	98.7-99.6	
Sapovirus	46	59	46/46	100	92.3-100	1,497/1,510	99.1	98.5-99.5	


- Sensitivity/Positive Percent Agreement (PPA) 100% for 12 targets
 - Y. enterocolitica only 1 detection
- . ≥94.5% for 7 others
- Not calculated for *E. histolytica*, *Vibrio* spp and *V. cholera*

. Se	rning tr munoc verely dy diar	raveler ompro ill rhea -	mised h	E. coli O157	
W	/hat	aboı	ıt C d	liff???	
Table 1. Summary of labo	ratory tests for <i>C di</i> c	fficile			
Laboratory Test ELISA for Antigen	Sensitivity	Specificity	Time to results Rapid	Comment Cannot distinguish between toxigenic	
ELISA for Toxin	High Low	Low High	Rapid	and non-toxigenic strains Easy to perform; poor sensitivity	
PCR for toxigenic genes	High	High	Rapid	Cannot distinguish between active infection and asymptomatic carriage; more expensive than ELISA	
Cytotoxin Assay	High	High	Slow (24-48hrs)	Gold standard; requires tissue culture facility	

20 year old previously healthy female presents to the ED with cough, fever and headache. Lumbar puncture is performed: WBC 5 cells/µl (98% lymphs), RBC 8 cells/µl, glucose 50 mg/dl and protein 45 mg/dl. Multiplex CSF PCR is positive for HHV-6...




- 1560 prospectively collected samples
 - _o 136 (8.7%) positive
 - 5% in the adult population
- SEN/PPA 100% for 9/14, SPE/NPA >99.2%
- Enterovirus and HHV6 accounted for 54% of positive samples
- High number of false positives for *Cryptococcus* and *S. pneumoniae*



- . If LP was done after antibiotics
- . Suspect viral entity
- . Immunocompromised hosts

72 year old man with history of COPD presents to ED in mid February with worsening shortness of breath. He did not get his influenza vaccine. Respiratory rate is 30 breaths/min and O₂ sat 86%, he becomes progressively more confused and requires intubation. CXR shows bilateral atypical pneumonia...



Viruses	
Adenovirus	Human Rhinovirus/Enterovirus
Coronavirus HKU1, NL63, 229E, OC43 Human Metapneumovirus Respiratory Syncytial Virus	Influenza A, A/H1, A/H1-2009, A/H3, B Parainfluenza 1-4 Mers-CoV*
Bacteria	
Bordetella pertussis	Chlamydophila pneumoniae
Mycoplasma pneumoniae	Bordetella parapertussis*

			6		Specificity (%)	DOM: (CC)	A TRACTOR	Kappa (95% CI)
PRO /FA	PRO*/FA*	PRO*/FA-	PRO"/FA+	Sensitivity (%)		PPV (%)	NPV (%)	
181	6	5	0	54.5	100	100	97.3	0.69 (0.43-0.96)
191	1	0	0	100	100	100	100	1
191	1	0	0	100	100	100	100	1
180	12	0	0	100	100	100	100	1
187		0	2	100	98.9	60.0	100	0.75 (0.39-1)
179		0	3	100	98.4	76.9	100	0.86 (0.71-1)
181	10	0	1	100	99.5	90.9	100	0.95 (0.85-1)
	191 191 180 187	191 1 191 1 180 12 187 3 179 10	191 1 0 191 1 0 180 12 0 187 3 0 179 10 0	191 1 0 0 191 1 0 0 180 12 0 0 187 3 0 2 179 10 0 3	191 1 0 0 100 191 1 0 0 100 180 12 0 0 100 187 3 0 2 100 179 10 0 3 100	191 1 0 0 100 100 191 1 0 0 100 100 180 12 0 0 100 100 187 3 0 2 100 98.9 179 10 0 3 100 98.4	191	191

(n = 185) ^v (n = 200) ^h (n = 200) influenza A virus 32 32 33 influenza B virus 7 7 7 7 ISV 36 45 37 41 ininovirus/enterovirus 6 43 41 43 41 6 15 46 15 10		1	No. detected by:	
nfluenza B virus 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	Virus			xTAG RVF $(n = 200)^c$
SSV 36 45 37 himovirus/enterovirus 6 43 41 arainfluenza virus 14 16 15 denovirus 11 10 10 fetapneumovirus 7 6	Influenza A virus	32	32	33
thinovirus/enterovirus 6 43 41 arainfluenza virus 14 16 15 denovirus 11 10 10 fetapneumovirus 7 6	Influenza B virus	7	7	7
arainfluenza virus 14 16 15 adenovirus 11 10 10 Metapneumovirus 7 6	RSV	36	45	37
denovirus 11 10 10 Metapneumovirus 7 6	Rhinovirus/enterovirus	6	43	41
Metapneumovirus 7 6	Parainfluenza virus	14	16	15
	Adenovirus	11	10	10
lone (negative) 82 62 68	Metapneumovirus		7	6
	None (negative)	82	62	68
otal no. of viruses 106 160 149	Total no. of viruses	106	160	149

 Be aware of what rapid testing is available at your facility

Antimicrobial and diagnostic stewardship:

- . How will the test change your treatment?
- . Consider costs
- . Understand the limitations of these tests
 - PCR detects both alive and dead organisms
 - . Be aware of specific test characteristics

Test	PAMC	AKH	СРН	SPH
Influenza A & B	~	~	~	~
C. diff	~	~	~	~
MRSA (nasal)	~	~	~	
GBS (vag/rectal)	~	~		~
CT/GC	~	~	~	
MTB-Rif	✓		✓	
HSV 1,2 (mucous)	✓			✓

Gram Positive Bacterial	Gram Negative Bacteria
Enterococcus	Acinetobacter baumannii
Listeria monocytogenes	Haemophilus influenzae
Staphylococcus spp	Neisseria meningitidis
Staphylococcus aureus	Pseudomonas aeruginosa
Streptococcus spp	Enterobacteriaceae
Streptococcus agalactiae	Enterobacter cloacae complex
Streptococcus pneumoniae	Escherichia coli
Streptococcus pyogenes	Klebsiella oxytoca
	Klebsiella pneumoniae
	Proteus
	Serratia marcescens

Candida albicans
Candida glabrata
Candida krusei
Candida parapsilosis
Candida tropicalis
0

References	
 Messacar, Kevin, et al. "Implementation of Rapid Molecular Infectious Disease Diagnostics: the Role of Diagnostic and Antimicrobial Stewardship." Journal of Clinical Microbiology, vol. 55, no. 3, 2016, pp. 715–723., doi:10.1128/jcm.02264-16. Weile, Jan, and Cornelius Knabbe. "Current Applications and Future Trends of Molecular Diagnostics in Clinical Bacteriology." Analytical and Bioanalytical Chemistry, vol. 394, no. 3, 2009, pp. 731–742., doi:10.1007/s00216-009-2779-8. Garibyan, Lilit, and Nidhi Avashia. "Polymerase Chain Reaction." Journal of Investigative Dermatology, vol. 133, no. 3, 2013, pp. 1-4., doi:10.1038/jid.2013.1. FilmArray™ Gastrointestinal Panel. FilmArray™ Gastrointestinal Panel, BioFire, 2014, www.biofiredx.com/wp-content/uploads/2016/03/IS-MRKT-PRT-0234-07-FilmArray-Gastrointestinal-Panel-Information-Sheet.pdf. Poritz, Mark A., et al. "FilmArray, an Automated Nested Multiplex PCR System for Multi-Pathogen Detection: Development and Application to Respiratory Tract Infection." PLoS ONE, vol. 6, no. 10, 2011, doi:10.1371/journal.pone.0026047. 	
	1
 Schreckenberger, Paul C., and Alexander J. McAdam. "Point-Counterpoint: Large Multiplex PCR Panels Should Be First-Line Tests for Detection of Respiratory and Intestinal Pathogens." Journal of Clinical Microbiology, vol. 53, no. 10, 2015, pp. 3110–3115., doi:10.1128/jcm.00382-15. Buss, Sarah N., et al. "Multicenter Evaluation of the BioFire FilmArray Gastrointestinal Panel for Etiologic Diagnosis of Infectious Gastroenteritis." Journal of Clinical Microbiology, vol. 53, no. 3, 2015, pp. 915–925., doi:10.1128/jcm.02674-14. Solomon, D. A., and D. A. Milner. "ID Learning Unit: Understanding and Interpreting Testing for Clostridium Difficile." Open Forum Infectious Diseases, vol. 1, no. 1, 2014, doi:10.1093/ofidio/fu007. Leber, Amy L., et al. "Multicenter Evaluation of BioFire FilmArray Meningitis/Encephalitis Panel for Detection of Bacteria, Viruses, and Yeast in Cerebrospinal Fluid Specimens." Journal of Clinical Microbiology, vol. 54, no. 9, 2016, pp. 2251–2261., doi:10.1128/jcm.00730-16. Parker, Jayme. Alaska State Virology Laboratory (ASVL) Weekly Report – Week #12. Alaska Department of Health and Social Services, 2019, pp. 1–1, Alaska State Virology Laboratory (ASVL) Weekly Report – Week #12. 	
Loeffelholz, M. J., et al. *Comparison of the FilmArray Respiratory Panel and Prodesse	
 Loerteinotz, M. J., et al. Comparison of the HimArray Respiratory Parties and Processe Real-Time PCR Assays for Detection of Respiratory Pathogens." <i>Journal of Clinical Microbiology</i>, vol. 49, no. 12, 2011, pp. 4083–4088., doi:10.1128/jcm.05010-11. Rand, Kenneth H., et al. "Comparison of Two Multiplex Methods for Detection of Respiratory Viruses: FilmArray RP and XTAG RVP." <i>Journal of Clinical Microbiology</i>, vol. 49, no. 7, 2011, pp. 2449–2453., doi:10.1128/jcm.02582-10. 	

Recommended F	Reading
---------------	---------

- Park, Sholhui, et al. "Is Follow-Up Testing with the FilmArray Gastrointestinal Multiplex PCR Panel Necessary?" Journal of Clinical Microbiology, vol. 55, no. 4, 2017, pp. 1154–1161., doi:10.1128/jcm.02354-16.
- Beal, Stacy G, et al. "A Gastrointestinal PCR Panel Improves Clinical Management and Lowers Health Care Costs." Journal of Clinical Microbiology, vol. 56, no. 1, 2017, doi:10.1128/jcm.01457-17.

 Hitchcock, Matthew M., et al. "Low Yield of FilmArray GI Panel in Hospitalized Patients with
- Diarrhea: an Opportunity for Diagnostic Stewardship Intervention." *Journal of Clinical Microbiol* vol. 56, no. 3, 2017, doi:10.1128/jcm.01558-17.
- vol. 39, no. 3, 2017, doi:10.11.20jcilin.01356-17.
 Hanson, Kimberly E. "The First Fully Automated Molecular Diagnostic Panel for Meningitis and Encephalitis: How Well Does It Perform, and When Should It Be Used?" Journal of Clinical Microbiology, vol. 54, no. 9, 2016, pp. 2222–2224, doi:10.1182/jcm.01255-16.
 Soucek, Dana K., et al. "Cost Justification of the BioFire FilmArray Meningitis/Encephalitis Panel
- Soulcek, Dana R., et al. Cost usumination of the born retirement, including in the properties of the p
- Viruses." Journal of Clinical Microbiology, vol. 51, no. 5, 2013, pp. 1528–1533., doi:10.1128/jcm.03368-12.

Special	Thanks!
Special	I HAHHE

Lynn Parish, Microbiology Supervisor Central Peninsula Ana Marie Inocencio CLS, MT (AMT), M(ASCP)cm,

Microbiology Supervisor Providence

Jenny Mayo, Infection Prevention Coordination Regional Sarah Miller, South Peninsula Microbiology Lead